Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome

11Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10). After 3 months, both treatments had similar effects on androgen levels, lipid profile, insulin sensitivity, and serum inflammatory markers, but flow-mediated dilatation increased by 69.0% in the metformin plus OC group while it remained unchanged in the OC group. Copyright © 2011 American Society for Reproductive Medicine, Published by Elsevier Inc.

Cite

CITATION STYLE

APA

Essah, P. A., Arrowood, J. A., Cheang, K. I., Adawadkar, S. S., Stovall, D. W., & Nestler, J. E. (2011). Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility, 96(2). https://doi.org/10.1016/j.fertnstert.2011.05.091

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free